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Objective: To understand the impact of platelet associated immunoglobulin G (PAIgG)/
platelet associated immunoglobulin M (PAIgM) on severity of dengue virus infection
leading to thrombocytopenia.
Methods: In this study we examined a total of 52 patients who were having secondary
infection of dengue in acute phase by using competitive ELISA.
Results: A decrease in the platelet count was observed at the acute phase of infection
while all along the recovery stage the count of platelet was signiﬁcantly increased. A
signiﬁcant decrease was observed in PAIgG and PAIgM in these subjects. Inverse cor-
relation was found between platelets count and PAIgG/PAIgM among the subjects
studied. In the platelets elution from ten subjects, anti-dengue virus immunoglobulin G
and immunoglobulin M were observed. PAIgG and PAIgM with inclined levels were
higher in dengue hemorrhagic fever than the classical dengue fever. In the development
of dengue hemorrhagic fever PAIgM inclined level was independently associated with
high speciﬁcity, showing a possible indication of dengue hemorrhagic fever.
Conclusions: This study suggests that in secondary dengue virus infection, the PAIgG
and PAIgM levels, and the activity of anti-dengue virus play key roles, both in the
development and severity of the disease.1. Introduction
The dengue-virus is a human viral pathogen, that is basically
mosquito borne, affecting about 2.5 billion peoples in tropical and
sub-tropical regions of the world. Dengue virus belongs to genus
Flavivirus, family Flaviviridae having 4 serotypes (DEN-1, 2, 3,
4) [1,2]. The transfer of virus often involves the viremic blood
ingestion by mosquitos' Aedes, then for viral replication, an 8–10 days period of incubation occurs, virus appears in the saliva
and from here may transfer to a human that is susceptible.
Oviposition is stimulated by the female mosquito as blood
meal, during the extrinsic incubation period this undergoes one
or more reproductive cycles, in this way virus enter the egg and
passed to the next generation of mosquitoes [3]. Type 1 and
type 4 of dengue virus has clinical manifestation with a wide
spectrum, these manifestations includes “thrombocytopenia”
and “increased vascular permeability” [4–7]. Severe dengue-
virus infection complexity may occur that causes dengue hem-
orrhagic fever (DHF), which induces thrombocytopenia, abnor-
malities in coagulation and leakage of plasma in children and
worse results in adults showing increased occurrence of bleeding,
shocks and organs failure [2,3,8,9].
In the dengue endemic areas secondary dengue virus infection
is commonly observed, and probably constitute a risk factor foran open access article under the CC BY-NC-ND
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highly endemic now. During the past three decades the number of
dengue patients has rapidly increased, and in tropical and sub-
tropical countries now dengue infection is a most important
community health concern [4,10]. Dengue is endemic in Pakistan
in the post-monsoon period with its usual peak. In the year 1985
for the ﬁrst time in Pakistan dengue was reported as undifferen-
tiated fever in children under 16 years of age. In 2011 Pakistan
had the worst strike of dengue, in which 2300 cases were re-
ported [11]. Although platelets synthesis decreases with dengue
induced bone marrow suppression, in patients with DHF
thrombocytopenia an immune mechanism is operative that
results in increased platelets destruction. In patients with
chronic idiopathic thrombocytopenia purpura an increased level
of platelets associated immunoglobulin G (PAIgG) has been
observed, but in a variety of other diseases it has been founded.
Oishi et al. studied that throughout the acute phase of
secondary dengue virus infection, there is an inverse correlation
between level of PAIgG and platelets count [12]. As the dengue
virus binds directly to the platelets, with this they speculated
that on the platelets the immune complex of the dengue virus
with anti-dengue virus are located. While formation of PAIgG
may play a part in the initiation of thrombocytopenia via both
of fragment crystallizable receptors- and complement receptors-
mediated platelets removal by the macrophages and comple-
ment mediated platelets lysis, development of platelets associated
immunoglobulin M (PAIgM) can also play a part in the initiation
of thrombocytopenia of thrombocytopenia through the same
mechanism (excluding the use of FC receptors) based on
immunoglobulin M (IgM) pentamer's function. As in DHF
thrombocytopenia is more common than in dengue fever so we
therefore assumed that increase in the level of PAIgG may be
linked with disease's severity, by developing thrombocytopenia
in dengue patients. Furthermore, although with secondary dengue
infection the number of IgM that are associated with platelets, is
also increased in this disease but the role of PAIgM remains
uncertain [12,13]. In secondary dengue virus infection, no studies
have been conducted in less developed country like Pakistan to
determine the levels and role of PAIgG/PAIgM for disease
severity and inducing thrombocytopenia. So, we in this hospital
based study determined the levels and correlation of PAIgG/
PAIgM with thrombocytopenia as well as the disease severity.
2. Materials and methods
2.1. Patients and specimen
At Hayat Abad Medical Complex (Peshawar, Pakistan), a
total of 122 clinically suspected patients of having dengue virus
infection were enrolled between August 2013 and December
2014. Of all these subjects, the number of diagnosed subjects
having acute phase dengue virus infection (3–7 days after the
onset of disease) was 83, as veriﬁed by screening tests i.e. IgM
capture ELISA and RT-PCR [14–16]. By using hemagglutination
inhibition test 75 subjects with the acute phase of secondary
dengue infection (3–7 days just after the onset of disease)
were diagnosed. By using the hemagglutination inhibition test,
7 subjects were diagnosed with a primary dengue infection. In
this study we evaluated platelet count, PAIgG and PAIgM at
the time of enrollment (acute phase) and then after 4 days
from the 1st test (convalescent phase) out of 52 patients.
During the same period at Hayat Abad Medical Complex,Peshawar as a control group 55 healthy volunteers with same
age were screened for IgM, platelets number and PAIgG/
PAIgM levels [17]. Ethylene diamine tetraacetic acid tubes
were drawn from the infected subjects and healthy volunteers.2.2. Platelets count
With automatic hemocytometer the platelet count was
determined. Through World Health Organization criteria DHF
was determined i.e. the platelets count must be 100 000 cells/
mm3, hematocrit elevation 20% above the average age group
and hemorrhagic manifestation [7,17]. All the DHF cases were
further grouped as I–IV. Dengue fever was deﬁned as an
elevation in hematocrit of < 20% and on the right lateral
decubitus chest radiograph with no detectable pleural effusion
[18]. Procedure for this study was approved by the Bioethics
Committee of Hayat Abad Medical Complex, Peshawar
Pakistan. Written informed consent was provided to parents
and guardians of all patients.
Hemagglutination inhibition test was performed according to
the method of Clarke and Casals [19], a paired plasma sample
with an interval longer than 7 days was used. When the
hemagglutination inhibition titer was 1:2560 in the plasma of
subjects having acute/convalescent phase, it was considered to
be a secondary infection [17,20].2.3. Competitive ELISA for PAIgG/PAIgM
The 96-wells ﬂat-bottomed microtitre polystyrene plates
were previously coated with standard-human immunoglobulin
M (IgG) (Inter. Cell Tech.) (400 ng/well) or with human-IgM
(ChemiCon Inter. USA). By following the protocol used by
Saito et al., the values of PAIgG/PAIgM were recorded as the
IgG/IgM values in ng/107 platelets count [17].2.4. Activity of anti-dengue virus IgG/IgM in the samples
of elute platelets
The platelets were separated from plasma samples of 10
subjects having acute phase of secondary infection (eight having
dengue fever while two were with DHF) and from the plasma of
six healthy volunteers. The activity of IgG/IgM (anti-dengue
virus) in the elute platelets samples was measured. Antibodies
were eluted from the separated platelets. At 4 C overnight the
elute was dialyzed against phosphate buffered saline, and were
concentrated to a ﬁnal volume of 1 mL containing 3 × 109
platelets by using a concentrator. Until use these samples were
stored at −80 C. The 96 wells ﬂat-bottomed microplates pre-
viously coated with 100 mL of a dengue-virus antigens mixture
(2.5 mg/mL) was used in the IgG/IgM indirect ELISA for the
detection of anti-dengue virus antigens [8,17]. For antigen
preparation dengue-type I (Hawaii Strain), type II (THNH7/93
strain), type III (PHNH4/84) and type IV (CT93-158) viruses
were used. After washing the plates, 50 mL of undiluted elutes
were added to the duplicate wells, following 30 min incubation
at room temperature [17]. The plate was washed and then it was
reacted with 100 mL alkaline phosphatase conjugated anti-
human IgG goat serum (1:5000 dilution, Biosource Int., USA)
or anti-human IgM goat serum (1:2500 dilution, Biosource Int.),
and then ﬁnally at 405 nm the optical density (OD) was
measured [17].
Figure 1. Correlation between platelets count (× 103/mL) and levels of
PAIgG (ng/107 platelet) (n = 52) (A) /PAIgM (ng/107 platelet) (n = 52) (B)
in patients having acute secondary phase dengue virus infection.
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All the data were expressed as mean ± SD. We used statis-
tical software, JMP, 10.0 SAS, USA for the analysis of platelets
count and PAIgG/PAIgM levels during the period between the
acute and convalescent phase. Platelets count and PAIgG/
PAIgM levels were analyzed between all healthy volunteers vs.
patients with dengue virus infection, and between patients with
dengue fever vs. DHF by the Mann–Whitney U-Test. On the
severity of disease a multivariate logistic regression was used to
assess the association of PAIgG/PAIgM and platelet count.
Using the Spearman's rank correlation the signiﬁcance of cor-
relation was estimated. The level of signiﬁcance was measured
as P < 0.05.
3. Results
Out of the 52 patients that were having secondary dengue
virus infection, 27 were diagnosed with dengue fever and 25
were diagnosed as DHF. The DHF patients were further grouped
into DHF I (n = 7) and DHF II (n = 18). Platelets-count, and
PAIgG/PAIgM were signiﬁcantly different (P < 0.001) in pa-
tients having acute-phase of secondary infection and healthy
individuals (Table 1). Statistically signiﬁcant (P < 0.001) vari-
ation was observed in the maximum percent hematocrit increase,
PAIgG/PAIgM among subjects with dengue fever and dengue
hemorrhagic fever, while difference in subjects age, period after
onset and platelets count was not signiﬁcant between these two
groups. We detected a signiﬁcant correlation (P < 0.0001,
r = −0.241) between platelets count and PAIgG level in total 52
patients having secondary dengue virus infection (Figure 1A).
We also observed a strong correlation (P < 0.0001, r = −0.335)
among these patients at the time of enrollment (Figure 1B). In 52
patients having secondary dengue infection, the change in
platelets count and PAIgG/PAIgM was compared between acute
and convalescent phases. In these patients platelets count with
low baseline [(45.6 ± 23.1) × 103/mL] during the acute phase,
increased signiﬁcantly (P < 0.001, Figure 2A) and improved to
normal count during the period of convalescing
[(242.7 ± 52.4) × 103/mL]. On the other hand, in the same
subjects during the acute phase the increased baseline PAIgG
[(28.3 ± 17.0) ng/107 platelet] or PAIgM [(21.3 ± 15.3) ng/107
platelet] decreased signiﬁcantly [P < 0.001 for PAIgG
(Figure 2B); P < 0.001 for PAIgM (Figure 2C)] during the
convalescent phase to a normal level for PAIgG [(5.04 ± 2.3) ng/
107 platelet] and [(3.1 ± 2.0) ng/107 platelet] for PAIgM. In the
elutes of the platelets samples the levels of antidengue virus IgG
or IgM were determined. In elutes from six healthy volunteers
the OD at 405 nm for antidengue virus IgG and IgM were
0.20 ± 0.10 and 0.09 ± 0.05, respectively. In contrast, in elutes
from the subjects in the acute phase of secondary infection, anTable 1
Laboratory data on patients with acute phase of secondary dengue virus infe
Diagnosis Number Age (years) Days after onset % Increase in hemat
HV 55 18.3 – –
DV Infection 52 17.8 5.9 ± 1.1 21.3 ± 5.6
DF 27 17.7 6.1 ± 0.1 10.7 ± 8.1
DHF 25 18.1 6.4 ± 1.1 25.5 ± 7.9**
HV: Healthy volunteer; DF: Dengue fever; PLT: Platelet; Data represent
***: P < 0.01 versus DF; ****: P < 0.001 versus DF.increased activity of anti-dengue virus IgG/IgM (OD 405 nm;
1.54 ± 0.35 for anti-dengue virus IgG, 0.35 ± 0.20 for anti-
dengue virus IgM) was found. In the patients with acute phase of
secondary infection we then examined whether the PAIgG/
PAIgM levels correlated directly with the hematocrit increase, as
for vascular permeability it is a critical indicator [21]. PAIgG
level and hematocrit percent increase correlates non-
signiﬁcantly (n = 52, r = 0.061, P > 0.05). A weak correlation
(n = 52, r = 0.21, P = 0.038) between the level of PAIgM and
percentage increase in hematocrit was observed, while no sig-
niﬁcant correlation was observed between subjects with dengue
fever (n = 27, r = −0.11, P > 0.05) and (n = 25, r = −0.29,
P > 0.05) in patients with DHF. PAIgM was associated inde-
pendently with DHF among parameters of platelets count,
PAIgG and PAIgM (P < 0.001) as demonstrated by a logistic
regression. As an interpreter for the subsequent progression of
DHF a level of PAIgM higher than 20 ng/107 platelets with action and healthy volunteers.
ocrit PLT count (103/mL) PAIgG (ng/107 PLT) PAIgM (ng/107 PLT)
261.1 ± 68.2 12.2 ± 3.1 5.8 ± 1.1
45.6 ± 23.1* 28.3 ± 17.0* 21.3 ± 15.3*
62.9 ± 17.5 23.0 ± 11.7 11.6 ± 6.6
27.0 ± 10.2 34.1 ± 20.0*** 31.8 ± 15.2****
as mean ± SD; *: P < 0.001 versus HV; **: P < 0.001 versus DF;
Figure 2. Comparing the peripheral platelets count (× 103/mL) (n = 52) (A), level of PAIgG (ng/107 platelet) (n = 52) (B) and level of PAIgM (ng/107
platelet) (n = 52) (C) between the acute (the ﬁrst test) and convalescent phase (4 days after the ﬁrst test) of secondary dengue virus infections.
*: P < 0.001.
Figure 3. Comparison of the levels of PAIgM (ng/107 platelet) between
patients with dengue fever (n = 27) and DHF (n = 25) during the acute
phase of a secondary dengue virus infection.
The horizontal broken line represents the cut-off value (20 ng/107 platelets)
for the prediction of DHF.
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observed during the acute phase of secondary infection
(Figure 3).
4. Discussion
In this study we revealed that platelets count is signiﬁcantly
correlated with PAIgG as well as PAIgM levels in acute phase of
secondary dengue virus infection. The PAIgG/PAIgM levels in
acute phase were signiﬁcantly higher than in the convalescent
phase. Levels of PAIgG and PAIgM were found to be similar
during acute and convalescent phases. Although antidengue vi-
rus IgG were relatively higher than antidengue virus IgM ac-
tivities, we found that in elutes from patients in acute phase of
secondary infection, the activity of both the anti-dengue virus
IgG/IgM were increased. In the patients of acute phase of sec-
ondary dengue virus infection these data indicates that the
PAIgM formation involving anti-dengue virus IgM may also
contributes for inducing thrombocytopenia. By transient for-
mation of PAIgG for thrombocytopenia as shown by Oishio
et al. throughout acute phase of the secondary infection,
development of PAIgM may also play a part for inducing
thrombocytopenia [8]. While by formation of PAIgG may play a
role in the induction of thrombocytopenia via both of fragment
crystallizable receptors- and complement receptors-mediated
platelets removal by the macrophages and complement medi-
ated platelets lysis, development of PAIgM can also play a role
in the induction of thrombocytopenia via the same mechanism(excluding the use of FC receptors) based on IgM pentamer's
function [22,23]. Previously a study reported that in the existence
of a virus-speciﬁc antibody, virus of dengue-2 sticks to the
platelets [17,24]. By Satio et al. in a study among 21 patients with
secondary dengue infection, observed a high positive rate of
42.85 with dengue-virus RNA in puriﬁed platelets samples
through RT-PCR [17]. This data indicates that dengue-virus is
present on the circulating platelets in subjects having secondary
dengue infection, this supports our assumption of a procedure of
inducing thrombocytopenia by involving the development of
PAIgG/PAIgM. The increase in the PAIgG/PAIgM levels was
signiﬁcant, and we also observed that there was a signiﬁcant
correlation between PAIgG/PAIgM levels and platelets count in
patients having acute secondary phase infection, the PAIgG in 8
patients (29.6%) and PAIgM in 17 patients (68%) levels per-
sisted within normal range (0–14.9 ng/107 platelets in case of
PAIgG, while 0–12 ng/107 platelets in case of PAIgM). So our
data indicates that in these patients other methods may also be
operative that are involve in the development of thrombocyto-
penia. The contribution of PAIgG appears to be much greater
than that of PAIgM for induction of thrombocytopenia. As
prognosticator of DHF other studies had recommended some
host factors i.e. (a) soluble vascular cell adhesion molecule 1, (b)
dengue-virus non-structural protein and (c) soluble tumor ne-
crosis factor-receptors [25,26]. In this study PAIgM level
increased was highly speciﬁc (92.5%) although its sensitivity
was relatively low (32%), for the development of DHF
throughout acute secondary phase infection. Now we could
say that it is quite possible that development of PAIgM is
contributing to the increasing vascular permeability.
Krishnamurti et al. demonstrated the platelets binding to the
endothelial cells that were infected with dengue-virus [27,28].
As vascular permeability increases with DHF, so for this
mechanism active platelets that are associated with dengue-
virus, anti-dengue virus IgM and endothelial cells that are
infected with dengue-virus may be important [9,17,29]. In short,
we have demonstrated that throughout the acute secondary
phase dengue virus infection, the inclined PAIgG/PAIgM
levels, anti-dengue virus IgG and IgM are closely linked with
thrombocytopenia [17,30,31]. With development of DHF, PAIgM
was independently associated throughout the acute secondary
phase infection, and for DHF it was highly speciﬁc. In the
mechanism of inducing thrombocytopenia via increasing
vascular permeability, development of PAIgG/PAIgM may
play a leading role. Further research and interpretations are
required to illuminate and link the platelets associated
immunoglobulins with the methods of development of
thrombocytopenia via increase vascular permeability.
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